Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. When you hear about osteoporosis, what kind of patient do you picture?
Abaloparatide-Patch patient assessment study results demonstrated high patient acceptability and self-administration accuracy over a 29-day period Levels of PINP, a biomarker for bone formation, after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results